Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Moderna Inc (NQ: MRNA )

65.69 -2.33 (-3.43%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 12,421,483
Open 67.60
Bid (Size) 65.61 (3)
Ask (Size) 65.68 (7)
Prev. Close 68.02
Today's Range 64.70 - 67.91
52wk Range 62.55 - 170.47
Shares Outstanding 384,000,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Pfizer Advances On Its Cancer Journey
On Saturday, Pfizer Inc (NYSE: PFE) presented positive trial data for experimental drug designed for patients suffering from cancer cachexia during the European Society for Medical Oncology 2024... 
Via Benzinga
Down 13% in 1 Day, Is Moderna Stock in Trouble?
There's no hope of it recovering to its prior heights anytime soon. 
Via The Motley Fool

Performance

YTD
-41.61%
-41.61%
1 Month
-24.19%
-24.19%
3 Month
-50.76%
-50.76%
6 Month
-37.69%
-37.69%
1 Year
-34.46%
-34.46%

More News

Read More
3 Beaten-Down Stocks Ready for a Comeback
Via MarketBeat
Topics Economy
Exposures Economy
Novo Nordisk Just Took a $530 Million Step Onto Moderna's Turf. Here's What It Means for Both Stocks
Via The Motley Fool
Moderna, Inc. REMINDER – MRNA Stockholders Should Contact Robbins LLP for Information About the Moderna, Inc. Class Action and Pending Lead Plaintiff Deadline
From Robbins LLP
Via GlobeNewswire
16 Analysts Have This To Say About Moderna
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Jim Cramer Labels Moderna A 'Big Disappointment,' But Suggests Doubling Down On Another Pharma Powerhouse
Via Benzinga
Prediction: These Could Be the Best-Performing Biotech Stocks Through 2030
Via The Motley Fool
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Moderna, Lululemon, XPEL, and Nano Nuclear and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
S&P 500 Briefly Hits Record High Just Ahead Of Fed Rate Cut, Extends 7-Day Winning Streak: Tuesday's Top 5 Gainers
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
Momentum Investing Gives You An Edge, Until It Doesn’t
Via Talk Markets
Small Caps, Bitcoin Rally As Traders Await Fed Rate Cut; Treasury Yields, US Dollar Tick Up On Strong Retail Sales: What's Driving Markets Tuesday?
Via Benzinga
Topics Economy
Exposures Interest Rates
What's Going On With Moderna Shares Tuesday?
Via Benzinga
Exposures COVID-19
Moderna Receives Health Canada Approval For Updated COVID-19 Vaccine Targeting KP.2 Variant Of SARS-COV-2 For Ages Six Months And Older
Via ACCESSWIRE
MODERNA, INC. (NASDAQ: MRNA) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Moderna, Inc. Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
DeSantis Administration Cautions Against Pfizer, Moderna mRNA Covid Vaccines for Vulnerable Individuals, Cites Concerns Related To Rare Heart Conditions
Via Benzinga
Exposures COVID-19
Moderna’s Recent Drop: 4 Reasons Bulls See Opportunity
Via MarketBeat
Exposures COVID-19 Product Safety
Moderna, Tyson Foods And Adobe Are Among Top 10 Large Cap Stock Losers Last Week (Sep 8-Sep 14): Are The Others In Your Portfolio?
Via Benzinga
Down More Than 50%, Is It Time to Buy Moderna Stock as the Biotech Charts a New Post-COVID Path?
Via The Motley Fool
Wall Street's Top 10 Stock Calls This Week - Saturday, Sept. 14
Via Talk Markets
Investing in Biotech or Pharma Stocks? Pay Attention to These 3 Things and You'll Win More
Via The Motley Fool
After Moderna's Shocking News, Is the Stock a Buy or a Sell?
Via The Motley Fool
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Moderna, Lululemon, XPEL, and Nano Nuclear and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Moderna Faces Analyst Downgrades Amid Revised R&D Restructured Strategy and Delayed Profitability Target
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.